Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MOMENTA PHARMACEUTICALS INCMNTA · Entity 146313 | SVP, CFO | December 15, 2016 | December 16, 2016 |
| SYNLOGIC, INC.SYBX · Entity 7801 | Director | April 26, 2025 | April 29, 2025 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Chief Financial Officer | February 12, 2020 | February 14, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MOMENTA PHARMACEUTICALS INC
Report date December 15, 2016 · Filed December 16, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 119,906 |
Ending reported balance
After 2016-12-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-12-15 · Sale · Disposed 7,733 · Balance 121,972 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016. Row 2 · 2016-12-15 · Sale · Disposed 2,066 · Balance 119,906 F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016.
SYNLOGIC, INC.
Report date April 26, 2025 · Filed April 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,506 |
Reported balance
After 2025-04-26 transaction · row 1
1 source rowRow 1 · 2025-04-26 · Grant · Acquired 15,000 · Balance 15,506 F1: Per the Amended and Restated Non-Employee Director Compensation Program, amended on April 26, 2025, and the 2015 Equity Incentive Award Plan, the Board of Directors of Synlogic, Inc. awarded each Non-Employee Director 15,000 shares of restricted stock. The shares were granted on April 26, 2025 and will fully vest on December 15, 2025, subject to the Reporting Person continuing to provide services to the Company as a Non-Employee Director, through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Per the Amended and Restated Non-Employee Director Compensation Program, amended on April 26, 2025, and the 2015 Equity Incentive Award Plan, the Board of Directors of Synlogic, Inc. awarded each Non-Employee Director 15,000 shares of restricted stock. The shares were granted on April 26, 2025 and will fully vest on December 15, 2025, subject to the Reporting Person continuing to provide services to the Company as a Non-Employee Director, through such vesting date.
Syndax Pharmaceuticals Inc
Report date February 12, 2020 · Filed February 14, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,121 |
Ending reported balance
After 2020-01-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-07-31 · Other · Acquired 1,401 · Balance 5,616 F1: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,401 shares by the Reporting Person on 07/31/2019 pursuant to the Issuer's Employee Stock Purchase Plan. Row 2 · 2020-01-31 · Other · Acquired 1,505 · Balance 7,121 F2: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,505 shares by the Reporting Person on 01/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.47 · Expires 2030-02-12 | Direct | 43,200 |
Reported balance
After 2020-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-12 · Grant · Acquired 43,200 · Balance 43,200 F3: 1/48th of the shares subject to the option shall vest monthly over a four-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,401 shares by the Reporting Person on 07/31/2019 pursuant to the Issuer's Employee Stock Purchase Plan.
F2: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,505 shares by the Reporting Person on 01/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan.
F3: 1/48th of the shares subject to the option shall vest monthly over a four-year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2025 Filed Apr 29, 2025 16:46 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-060267 · ownership.xml · nonDerivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,506 F1 · shares: Per the Amended and Restated Non-Employee Director Compensation Program, amended on April 26, 2025, and the 2015 Equity Incentive Award Plan, the Board of Directors of Synlogic, Inc. awarded each Non-Employee Director 15,000 shares of restricted stock. The shares were granted on April 26, 2025 and will fully vest on December 15, 2025, subject to the Reporting Person continuing to provide services to the Company as a Non-Employee Director, through such vesting date. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 14:28 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950170-23-029809 · ownership.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 16:15 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0000899243-22-022177 · doc4.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 17:13 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0000899243-21-023617 · doc4.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 17:31 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.22 | $0.00 |
DisclosureSEC source: 0000899243-20-015648 · doc4.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-04 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject to the non-employee director's continued service as a director of the Corporation. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 16:37 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 43,200 | $0.00 Strike: $9.47 | $0.00 |
DisclosureSEC source: 0001562180-20-001237 · primarydocument.xml · derivative · entry 3 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,200 Underlying: Common Stock · 43,200 shares Expires 2030-02-12 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| January 31, 2020 Filed Feb 14, 2020 16:37 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 1,505 | $7.97 | $11,994.85 |
DisclosureSEC source: 0001562180-20-001237 · primarydocument.xml · nonDerivative · entry 2 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,121 F2 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,505 shares by the Reporting Person on 01/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 17:25 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | PurchaseCommon Stock | 7,500 | $2.74 | $20,550.00 |
DisclosureSEC source: 0000899243-19-029298 · doc4.xml · nonDerivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Read SEC document |
| July 31, 2019 Filed Feb 14, 2020 16:37 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 1,401 | $4.89 | $6,850.89 |
DisclosureSEC source: 0001562180-20-001237 · primarydocument.xml · nonDerivative · entry 1 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,616 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,401 shares by the Reporting Person on 07/31/2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| June 05, 2019 Filed Jun 7, 2019 16:15 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0000899243-19-015994 · doc4.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to each non-employee director's continued service as a director of the Corporation. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 16:27 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 91,200 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-19-000854 · primarydocument.xml · derivative · entry 2 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,200 Underlying: Common Stock · 91,200 shares Expires 2029-02-06 F3 · derivative.exercise_date: The securities awarded on 02/06/2019 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 43,200 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/06/2019. Options to purchase 48,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document |
| January 31, 2019 Filed Feb 8, 2019 16:27 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | OtherCommon Stock | 2,521 | $4.76 | $11,999.96 |
DisclosureSEC source: 0001562180-19-000854 · primarydocument.xml · nonDerivative · entry 1 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,215 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 2,521 shares by the Reporting Person on 01/31/2019 pursuant to the Issuer's Employee Stock Purchase Plan. F2 · balance_after: Includes 1,694 shares cumulatively acquired pursuant to the Issuer's Employee Stock Purchase Plan on 01/31/2018 and 07/31/2018, respectively. Read SEC document |
| June 13, 2018 Filed Jun 14, 2018 16:05 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0000899243-18-016589 · doc4.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option vests and becomes exercisable in full on the earlier of (A) the first anniversary of the date of grant or (B) immediately prior to the next annual meeting of the Corporation's stockholders after the date of grant, subject in each case to the reporting person's continued service as a director of the Corporation. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 16:04 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $9.40 | $0.00 |
DisclosureSEC source: 0001562180-18-001429 · primarydocument.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: The stock option will vest in 48 successive equal monthly installments measured from February 8, 2018. Read SEC document |
| December 29, 2017 Filed Jan 3, 2018 16:30 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 17,143 | $0.00 Strike: $9.70 | $0.00 |
DisclosureSEC source: 0000899243-18-000273 · doc4.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,143 Underlying: Common Stock · 17,143 shares Expires 2027-12-29 F1 · derivative.exercise_date: The options vest and become exercisable in substantially equal installments on each of the first three anniversaries of August 28, 2017 subject to the Reporting Person continuing to provide services to the Issuer through each such vesting date. Read SEC document |
| August 28, 2017 Filed Aug 30, 2017 16:10 UTC | SYNLOGIC, INC. SYBX · Entity 7801 | GrantStock Option (right to buy) · Derivative | 2,857 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0000899243-17-021267 · doc4.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,857 Underlying: Common Stock · 2,857 shares Expires 2027-08-28 F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal installments on each of the first three anniversaries of the Transaction Date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 10:32 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $10.20 | $0.00 |
DisclosureSEC source: 0001562180-17-000692 · primarydocument.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-02-13 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares underlying the option shall vest on February 13, 2018, and one forty-eighth (1/48th) of the total number of shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 15:41 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 2,066 | $15.00 | $30,990.00 |
DisclosureSEC source: 0001179110-16-033097 · edgar.xml · nonDerivative · entry 2 Shea Richard P · CIK 0001294354 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,906 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 15:41 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 7,733 | $15.00 | $115,995.00 |
DisclosureSEC source: 0001179110-16-033097 · edgar.xml · nonDerivative · entry 1 Shea Richard P · CIK 0001294354 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,972 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016. Read SEC document |
| December 09, 2016 Filed Dec 12, 2016 16:32 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 1,451 | $15.00 | $21,765.00 |
DisclosureSEC source: 0001179110-16-032819 · edgar.xml · nonDerivative · entry 1 Shea Richard P · CIK 0001294354 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,705 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 17, 2016. Read SEC document |
| November 22, 2016 Filed Nov 23, 2016 10:46 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 227 | $14.40 | $3,268.80 |
DisclosureSEC source: 0001179110-16-032001 · edgar.xml · nonDerivative · entry 3 Shea Richard P · CIK 0001294354 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,156 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2008. Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 10:46 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 348 | $13.45 | $4,680.60 |
DisclosureSEC source: 0001179110-16-032001 · edgar.xml · nonDerivative · entry 2 Shea Richard P · CIK 0001294354 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,383 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2008. Read SEC document |
| November 21, 2016 Filed Nov 23, 2016 10:46 UTC | MOMENTA PHARMACEUTICALS INC MNTA · Entity 146313 | SaleCommon Stock | 396 | $13.45 | $5,326.20 |
DisclosureSEC source: 0001179110-16-032001 · edgar.xml · nonDerivative · entry 1 Shea Richard P · CIK 0001294354 · SVP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,731 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2008. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 17:25 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001562180-16-003356 · primarydocument.xml · derivative · entry 1 Shea Richard P · CIK 0001294354 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-10-31 F1 · derivative.exercise_date: One hundred percent (100%) of the total number of shares underlying the option shall vest on October 31, 2017, subject to the reporting person's continuous service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.